Efficacy and Safety of Electroacupuncture in the Treatment of Esophageal Symptoms in Non-erosive Reflux Disease (NERD) Patients
Investigating the Efficacy and Safety of Electroacupuncture in the Treatment of Esophageal Symptoms in Non-erosive Reflux Disease (NERD) Patients: A Pilot, Randomized Double-blinded, Sham-controlled Trial
The goal of this clinical trial is to learn if acupuncture works to treat non-erosive reflux disease (NERD) patients. The main questions it aims to answer are:
- Electroacupuncture (EA) is superior to sham EA in terms of easing the symptom severity of NERD.
- Acupuncture is able to influence gastrointestinal function, autonomic regulation, and stress responses in NERD patients.
Participants will:
- Receive acupuncture treatment twice per week for 6 weeks.
- Leave plasma, serum, saliva, stool, and urine samples at baseline, mid-treatment, and end-of-treatment.
- Complete patient-reported-outcomes (PROs) at baseline, mid-treatment, and end-of-treatment
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Linda LD Zhong, PhD
- Número de teléfono: +65 67911744
- Correo electrónico: linda.zhong@ntu.edu.sg
Copia de seguridad de contactos de estudio
- Nombre: Huangyan Chen
- Número de teléfono: +65 97663672
- Correo electrónico: huangyan001@e.ntu.edu.sg
Ubicaciones de estudio
-
-
-
Singapore, Singapur, S637551
- Nanyang Technological University, School of Biological Sciences
-
Contacto:
- Huangyan Chen
- Número de teléfono: +65 97663672
- Correo electrónico: huangyan001@e.ntu.edu.sg
-
Contacto:
- Linda LD Zhong, PhD
- Número de teléfono: +65 65921733
- Correo electrónico: linda.zhong@ntu.edu.sg
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Adults aged 21 to 75 years at the time of consent;
- Presence of heartburn, regurgitation or chest pain before screening with a frequency of at least twice a week;
- No evidence of esophageal mucosal injury on endoscopy within the past 5 years;
- GERD-Q score ≥8 (indicating active GERD symptoms);
- Ability and willingness to provide written informed consent to participate.
Exclusion Criteria:
-
Structural or organic gastrointestinal disease, including but not limited to:
- gastrointestinal malignancy,
- eosinophilic esophagitis,
- esophageal stricture, varices, or infections,
- active peptic ulcer disease,
- gastric or duodenal tumors;
-
Presence of alarming symptoms (e.g. severe dysphagia, hematemesis, unexplained weight loss, or hematochezia, etc.);
-
History of digestive tract surgery or esophageal interventions, including chemotherapy, radiotherapy, radiofrequency ablation, endoscopic mucosal resection, or cryotherapy;
-
Use of prohibited medical treatment:
- acupuncture treatment on the abdomen and chest within past 1 month,
- concomitant medication affecting gastrointestinal motility or visceral sensitivity (antidiarrheals, antidepressants, narcotic analgesics, anticholinergics, etc.),
- antibiotics, prebiotics, probiotics, or immunosuppressants within 1 month prior to screening;
-
Presence of an implanted cardiac pacemaker;
-
History of hypersensitivity to acupuncture, or needle phobia;
-
Severe psychiatric illness (e.g. schizophrenia, major depression, dementia), cognitive impairment, or other conditions likely to compromise adherence to study procedures;
-
Pregnant or breastfeeding;
-
Current participation in other clinical trials that could interfere with study outcomes.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Electroacupuncture (EA)
The WHO Standardized Acupuncture Points Location will be used to identify the location of these acupoints: ST36 Zusanli, PC6 Neiguan, CV12 Zhongwan, LR3 Taichong, SP4 Gongsun; and auxiliary acupoints added according to symptom severity: PC7 Daling, ST44 Neiting, EX-HN3 Yintang, ST37 Shangjuxu, SP6 Sanyinjiao, LU7 Lieque. After sterilizing the skin, needles of 0.25 mm in diameter and 25-40 mm in length will be inserted into the acupoints to a depth of 10-30 mm outward and upward slightly. Needles will be lifted, thrust, and twirled evenly 3 times to achieve "de-qi". Paired electrodes of the EA apparatus will be attached transversely to the acupoint respectively with a continuous wave of 2/100 Hz and a current intensity of 1-5 mA (preferably with the skin around the acupoints shivering mildly without pain) for 30 min. |
The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore. |
|
Comparador falso: Sham-electroacupuncture (SEA)
The sham electroacupuncture group (SEA) penetrates acupuncture on non-acupuncture points (1 B-cun away from the acupuncture point and meridian). The same type of acupuncture needles will be used for SEA with the exact skin sterilization method. Insertion depth will be approximately less than 10 mm. The electrostimulator will not be switched on for these patients. All needles will be removed after 30 min of needle retention. |
The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Gastroesophageal Reflux Disease Questionnaire (GERDQ)
Periodo de tiempo: From enrollment to the end of follow-up at 16 weeks
|
≥ 50% reduction in total GERD-Q score or normalization (<8) |
From enrollment to the end of follow-up at 16 weeks
|
|
Gastrointestinal Symptom Rating scale (GSRS)
Periodo de tiempo: From enrollment to the end of follow-up at 16 weeks
|
≥ 0.5 point decrease in mean GSRS Reflux domain value |
From enrollment to the end of follow-up at 16 weeks
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Quality of Life in Reflux and Dyspepsia questionnaire (QOLRAD)
Periodo de tiempo: From enrollment to the end of follow-up at 16 weeks
|
≥ 0.5 point improvement on the mean QOLRAD score |
From enrollment to the end of follow-up at 16 weeks
|
|
Euro QoL (EQ-5D-5L)
Periodo de tiempo: From enrollment to the end of follow-up at 16 weeks
|
change in index utility |
From enrollment to the end of follow-up at 16 weeks
|
|
Hospital Anxiety and Depression Scale (HADS)
Periodo de tiempo: From enrollment to the end of follow-up at 16 weeks
|
categorical shift from ≥ 11 to < 11 or ≥ 8 to < 8, or ≥ 1.5 point reduction per HADS-A and HADS-D subscale |
From enrollment to the end of follow-up at 16 weeks
|
|
Visceral Sensitivity Index (VSI)
Periodo de tiempo: From enrollment to the end of follow-up at 16 weeks
|
≥ 15% reduction from baseline |
From enrollment to the end of follow-up at 16 weeks
|
|
Esophageal Hypervigilance and Anxiety Scale (EHAS) Short Form
Periodo de tiempo: From enrollment to the end of follow-up at 16 weeks
|
≥ 15% reduction from baseline |
From enrollment to the end of follow-up at 16 weeks
|
|
Simplified Constitution of Chinese Medicine Questionnaire (CCMQ)
Periodo de tiempo: At baseline
|
At baseline
|
|
|
Traditional Chinese medicine functional gastrointestinal disorders syndrome scale (TCM-FGID)
Periodo de tiempo: From enrollment to the end of follow-up at 16 weeks
|
(Total syndrome score before treatment - Total syndrome score after treatment) / Total syndrome score before treatment × 100% |
From enrollment to the end of follow-up at 16 weeks
|
|
Bang's blinding index (BBI)
Periodo de tiempo: End of first week and sixth week of intervention
|
End of first week and sixth week of intervention
|
|
|
James' blinding index (JBI)
Periodo de tiempo: End of first week and sixth week of intervention
|
End of first week and sixth week of intervention
|
|
|
Patient's global impression of change (PGIC)
Periodo de tiempo: From mid-treatment to the end of follow-up at 16 week
|
From mid-treatment to the end of follow-up at 16 week
|
|
|
Daily patient diary
Periodo de tiempo: From enrollment to the end of follow-up at 16 weeks
|
From enrollment to the end of follow-up at 16 weeks
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Linda LD Zhong, PhD, Nanyang Technological University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- IRB-2025-1138
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
IPD sharing will be available upon request.
Marco de tiempo para compartir IPD
Data will become available within 7 years after completion of the clinical trial.
Criterios de acceso compartido de IPD
Individual participant data (IPD) will be made available to qualified researchers upon request. To access the data, researchers must submit a formal request, which will be reviewed and approved by the data-sharing committee. Data access will be granted for research purposes only and will require adherence to data use agreements and ethics guidelines.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
- CÓDIGO_ANALÍTICO
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .